The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

See a doctor who has experience with it. You’ll find dermatologists who have experience with cutaneous T-cell lymphoma at Find a Dermatologist. Click on "Filters". Select "Any condition" and choose ...

What’s a Sluggish Lymph System? Unless things have changed very suddenly, you can’t go to the doctor and get a test for a “sluggish lymph system,” unless perhaps you have lymphatic channels that are ...

Therapeutic options for relapsed follicular lymphoma include the same traditional regimens used for first-line therapy; however, they also include agents such as bendamustine, bortezomib ...

IDEXX will offer a new canine lymphoma test in the U.S. and Canada in late March. Shares of IDEXX Laboratories (IDXX) surged 10% to lead S&P 500 gainers Monday after the provider of veterinary ...

After a 12-year battle with stage IV Follicular Non-Hodgkin Lymphoma, Laurie found her path to remission through a groundbreaking CAR T-cell therapy trial. In this interview, she shares her ...

One possibility for this is that patients who have a blood test soon after surgery showing evidence of ctDNA have a higher risk to relapse and may benefit from additional therapies beyond standard ...

a diagnostic panel with early detection of lymphoma in canine patients. The new panel is an accessible blood test that can be added to the panels of sick pets and can be integrated into annual ...

But what also drives her goes well beyond the classroom. "When I was six, I was diagnosed with Stage 4 lymphoblastic lymphoma and that really shaped me as a person in a way that I was surrounded ...

Follicular lymphoma is a very diverse disease, and decisions to treat in the frontline are made based on histology, disease burden and patient symptoms. The general approach should be a ...